Interpreting geographic variations in results of randomized, controlled trials

New England Journal of Medicine

Volumn 375, Issue 23, 2016, Pages 2263-2271

  Yusuf, Salim ^a   Wittes, Janet ^b  

^a HAMILTON HEALTH SCIENCES   (Canada)

^b University of Iowa   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; MACITENTAN; MALARIA VACCINE; METOPROLOL;

CARDIOVASCULAR MORTALITY; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL STUDY; CONGESTIVE HEART FAILURE; ETHNIC DIFFERENCE; GEOGRAPHIC DISTRIBUTION; HEART FAILURE; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRAM DEVELOPMENT; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELIABILITY; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; STUDY DESIGN; CARDIOVASCULAR DISEASES; DEMOGRAPHY; MEDICAL GEOGRAPHY; MULTICENTER STUDY (TOPIC); TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; DEMOGRAPHY; GEOGRAPHY, MEDICAL; HUMANS; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 85001945981     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1510065     Document Type: Review

References (30)

1. Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991; 266: 93-8.
2. Yusuf S, Collins R, Peto R. Why do we need some large, simple randomized trials? Stat Med 1984; 3: 409-22.
3. Furberg CD, Byington RP. What do subgroup analyses reveal about differential response to beta-blocker therapy? The Beta-Blocker Heart Attack Trial experience. Circulation 1983; 67: I98-101.
4. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in highrisk patients. N Engl J Med 2000; 342: 145-53.
5. The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006; 354: 1464-76.
6. Pocock S, Calvo G, Marrugat J, et al. International differences in treatment effect: do they really exist and why? Eur Heart J 2013; 34: 1846-52.
7. Wittes J. Why is this subgroup different from all other subgroups? Thoughts on regional differences in randomized clinical trials. In: Fleming TR, Weir BS, eds. Proceedings of the fourth Seattle Symposium in Biostatistics: clinical trials. New York: Springer, 2013: 95-115.
8. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-7.
9. Wedel H, DeMets D, Deedwania P, et al. Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial. Am Heart J 2001; 142: 502-11.
10. Bristow MR, Murphy GA, Krause-Steinrauf H, et al. An alpha2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure. Circ Heart Fail 2010; 3: 21-8.
11. McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A∗3101 and carbamazepineinduced hypersensitivity reactions in Europeans. N Engl J Med 2011; 364: 1134-43.
12. Chen P, Lin J-J, Lu C-S, et al. Carbamazepine-induced toxic effects and HLAB∗ 1502 screening in Taiwan. N Engl J Med 2011; 364: 1126-33.
13. Zhang F-R, Liu H, Irwanto A, et al. HLA-B∗13:01 and the dapsone hypersensitivity syndrome. N Engl J Med 2013; 369: 1620-8.
14. RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 2015; 386: 31-45.
15. RTS,S Clinical Trials Partnership. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med 2014; 11(7): e1001685.
16. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-57.
17. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010; 55: 1915-22.
18. Center for Drug Evaluation and Research. Application number: 22-387 - approval letter. Silver Spring, MD: Food and Drug Administration, 2009 (http://www.accessdata.fda.gov/drugsatfda-docs/nda/2009/022387s000approv.pdf).
19. Center for Drug Evaluation and Research. Approval package for application number: 204410Orig1s000. Silver Spring, MD: Food and Drug Administration, 2013 (http://www.accessdata.fda.gov/drugsatfda -docs/nda/2013/204410Orig1s000Approv.pdf).
20. Draft briefing document for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC). Silver Spring, MD: Food and Drug Administration, 2013 (http://www.fda.gov/downloads/Advisory Committees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugs AdvisoryCommittee/UCM363541.pdf).
21. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014; 370: 1383-92.
22. Pfeffer MA, Claggett B, Assmann SF, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 2015; 131: 34-42.
23. Morillo CA, Marin-Neto JA, Avezum A, et al. Randomized trial of benznidazole for chronic Chagas' cardiomyopathy. N Engl J Med 2015; 373: 1295-306.
24. World Health Organisation European Collaborative Group. European collaborative trial of multifactorial prevention of coronary heart disease: final report on the 6-year results. Lancet 1986; 1: 869-72.
25. Khandelwal M. Vaginal progesterone in risk reduction of preterm birth in women with short cervix in the midtrimester of pregnancy. Int J Womens Health 2012; 4: 481-90.
26. Columbia Laboratories. Advisory Committee for Reproductive Health Drugs. NDA 22-139 for progesterone gel 8%. 15 Dec 2011 - briefing materials. 2011 (http://www.fda.gov/downloads/Advisory Committees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisory Committee/UCM287988.pdf).
27. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369: 809-18.
28. Huo Y, Li J, Qin X, et al. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. JAMA 2015; 313: 1325-35.
29. Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354: 1567-77.
30. Anand S, Yusuf S, Xie C, et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007; 357: 217-27.